Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01051661
Registration number
NCT01051661
Ethics application status
Date submitted
14/01/2010
Date registered
18/01/2010
Date last updated
26/02/2021
Titles & IDs
Public title
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
Query!
Scientific title
A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age
Query!
Secondary ID [1]
0
0
114000
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Influenza
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Other interventions - GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Other interventions - Placebo
Experimental: Arepanrix 2D 6M-3Y Group - Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
Experimental: Arepanrix 2D 3Y-10Y Group - Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
Experimental: Arepanrix 1D 6M-3Y Group - Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
Experimental: Arepanrix 1D 3Y-10Y Group - Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
Experimental: GSK2340273A 6M-3Y Group - Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
Experimental: GSK2340273A 3Y-10Y Group - Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
Other interventions: GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)
Intramuscular injection, one or two doses
Other interventions: GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
Intramuscular injection, two doses
Other interventions: Placebo
Intramuscular injection, one dose
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects Reporting at Least One A/California Influenza Event
Query!
Assessment method [1]
0
0
The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [1]
0
0
From 14 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [1]
0
0
Number of Subjects Reporting at Least One A/California Influenza Event
Query!
Assessment method [1]
0
0
The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [1]
0
0
From 42 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [2]
0
0
Number of Subjects Reporting at Least One A/California Influenza Event
Query!
Assessment method [2]
0
0
The influenza virus presence was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [2]
0
0
From Day 0 until study conclusion on Day 385
Query!
Secondary outcome [3]
0
0
Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event
Query!
Assessment method [3]
0
0
The influenza virus presence was confirmed by a positive culture.
Query!
Timepoint [3]
0
0
From 14 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [4]
0
0
Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event
Query!
Assessment method [4]
0
0
The influenza virus presence was confirmed by a positive culture.
Query!
Timepoint [4]
0
0
From 42 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [5]
0
0
Number of Subjects Reporting at Least One Culture Confirmed A/California Influenza Event
Query!
Assessment method [5]
0
0
The influenza virus presence was confirmed by a positive culture.
Query!
Timepoint [5]
0
0
From Day 0 until study conclusion on Day 385
Query!
Secondary outcome [6]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
From 14 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [7]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
From 42 days after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [8]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
From Day 0 after first vaccination until study conclusion on Day 385
Query!
Secondary outcome [9]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [9]
0
0
Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [9]
0
0
From 14 days after first vaccination until study conclusion at Day 385
Query!
Secondary outcome [10]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [10]
0
0
Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [10]
0
0
From 42 days after first vaccination until study conclusion at Day 385
Query!
Secondary outcome [11]
0
0
Number of Subjects With at Least One Pneumonia Event
Query!
Assessment method [11]
0
0
Pneumonia was confirmed by quantitative reverse transcription polymerase chain reaction assay (RT-qPCR).
Query!
Timepoint [11]
0
0
From Day 0 after first vaccination until study conclusion at Day 385
Query!
Secondary outcome [12]
0
0
Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases
Query!
Assessment method [12]
0
0
Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.
Query!
Timepoint [12]
0
0
From Day 0 until study end at Day 385
Query!
Secondary outcome [13]
0
0
Number of Subjects With Protocol Specified Influenza-like Illness (ILI) Symptoms in All Reported ILI Cases
Query!
Assessment method [13]
0
0
Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.
Query!
Timepoint [13]
0
0
From Day 14 until study end at Day 385
Query!
Secondary outcome [14]
0
0
Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases
Query!
Assessment method [14]
0
0
Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue.
Query!
Timepoint [14]
0
0
From Day 0 until study end at Day 385
Query!
Secondary outcome [15]
0
0
Number of Subjects With Protocol Specified ILI Symptoms in RT-qPCR-confirmed A/California Influenza Cases
Query!
Assessment method [15]
0
0
Protocol specified ILI symptoms were: fever, muscle aches all over the body, cough, sore throat, runny or stuffy nose, short of breath, headache, vomiting, diarrhea, chills and fatigue. Analysis for the time frame Day 42 till Day 385 was not performed as planned per protocol.
Query!
Timepoint [15]
0
0
From Day 14 until study end at Day 385
Query!
Secondary outcome [16]
0
0
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Query!
Assessment method [16]
0
0
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Query!
Timepoint [16]
0
0
During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses
Query!
Secondary outcome [17]
0
0
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged 6 Months to Less Than 6 Years
Query!
Assessment method [17]
0
0
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (=) 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness which prevented normal everyday activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 temperature = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Query!
Timepoint [17]
0
0
During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses
Query!
Secondary outcome [18]
0
0
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Children Aged Between 6 to 10 Years
Query!
Assessment method [18]
0
0
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (gastro.sympt.), headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (=) 38.0 degrees Celsius (°C)]. Any = Incidence of a particular symptom regardless of intensity grade or relationship to study vaccination. Grade 3 = symptom which prevented normal everyday activity. Grade 3 temperature = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Query!
Timepoint [18]
0
0
During the 7-day follow-up period (Day 0 - Day 6) after each dose and across doses
Query!
Secondary outcome [19]
0
0
Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)
Query!
Assessment method [19]
0
0
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Query!
Timepoint [19]
0
0
Up to Day 385
Query!
Secondary outcome [20]
0
0
Number of Subjects With Any Medically-attended Adverse Events (MAEs)
Query!
Assessment method [20]
0
0
MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.
Query!
Timepoint [20]
0
0
Up to Day 385
Query!
Secondary outcome [21]
0
0
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Query!
Assessment method [21]
0
0
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [21]
0
0
From Day 0 to Day 42
Query!
Secondary outcome [22]
0
0
Number of Subjects With Serious Adverse Events (SAEs)
Query!
Assessment method [22]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Query!
Timepoint [22]
0
0
Up to Day 385
Query!
Secondary outcome [23]
0
0
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [23]
0
0
Titers are presented as geometric mean titers (GMTs).
Query!
Timepoint [23]
0
0
At Days 0 and 42
Query!
Secondary outcome [24]
0
0
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [24]
0
0
A seropositive subject was defined as a subject whose HI titers were greater than or equal to (=) 1:10.
Query!
Timepoint [24]
0
0
At Days 0 and 42
Query!
Secondary outcome [25]
0
0
Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [25]
0
0
Seroconversion was defined as: for initially seronegative subjects, antibody titer = 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination = 4 fold the pre-vaccination antibody titer.
Query!
Timepoint [25]
0
0
At Day 42
Query!
Secondary outcome [26]
0
0
Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [26]
0
0
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer = 1:40.
Query!
Timepoint [26]
0
0
At Days 0 and 42
Query!
Secondary outcome [27]
0
0
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [27]
0
0
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post-vaccination compared to Day 0.
Query!
Timepoint [27]
0
0
At Day 42
Query!
Secondary outcome [28]
0
0
Geometric Mean Antibody Titer Ratio Adjusted for Baseline Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)
Query!
Assessment method [28]
0
0
The geometric mean titer ratio (GMT ratio) was defined as the ratio of geometric mean of the post-vaccination reciprocal HI titer between groups. The analysis was not performed for Day 182 and Day 385 as planned per protocol.
Query!
Timepoint [28]
0
0
At Day 42
Query!
Secondary outcome [29]
0
0
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1)
Query!
Assessment method [29]
0
0
Titers are presented as geometric mean titers (GMTs).
Query!
Timepoint [29]
0
0
At Days 0 and 182
Query!
Secondary outcome [30]
0
0
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [30]
0
0
A seropositive subject was defined as a subject whose HI titers were greater than or equal to (=) 1:10.
Query!
Timepoint [30]
0
0
At Days 0 and 182
Query!
Secondary outcome [31]
0
0
Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [31]
0
0
Seroconversion was defined as: for initially seronegative subjects, antibody titer = 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination = 4 fold the pre-vaccination antibody titer.
Query!
Timepoint [31]
0
0
At Day 182
Query!
Secondary outcome [32]
0
0
Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [32]
0
0
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer = 1:40.
Query!
Timepoint [32]
0
0
At Days 0 and 182
Query!
Secondary outcome [33]
0
0
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [33]
0
0
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
Query!
Timepoint [33]
0
0
At Day 182
Query!
Secondary outcome [34]
0
0
Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [34]
0
0
Titers are presented as geometric mean titers (GMTs).
Query!
Timepoint [34]
0
0
At Days 0 and 385
Query!
Secondary outcome [35]
0
0
Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [35]
0
0
A seropositive subject was defined as a subject whose HI titers was greater than or equal to (=) 1:10.
Query!
Timepoint [35]
0
0
At Days 0 and 385
Query!
Secondary outcome [36]
0
0
Number of Seroconverted (SCR) Subjects for Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [36]
0
0
Seroconversion was defined as: for initially seronegative subjects, antibody titer = 1:40 after vaccination; and for initially seropositive subjects, antibody titer after vaccination = 4 fold the pre-vaccination antibody titer.
Query!
Timepoint [36]
0
0
At Day 385
Query!
Secondary outcome [37]
0
0
Number of Seroprotected (SPR) Subjects Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [37]
0
0
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer = 1:40.
Query!
Timepoint [37]
0
0
At Days 0 and 385
Query!
Secondary outcome [38]
0
0
Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 (H1N1) Influenza Strain
Query!
Assessment method [38]
0
0
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
Query!
Timepoint [38]
0
0
At Day 385
Query!
Eligibility
Key inclusion criteria
- Male or female children 6 months to less than 10 years of age at the time of the first
vaccination. "Less than 10 years of age" implies inclusion of children who have not
reached their 10th birthday as of Day 0, the day of first vaccine dose under this
protocol.
- Written informed consent obtained from the subject's parent(s)/legally acceptable
representative(s) (LAR(s)); written informed assent obtained from the subject if
appropriate pre local requirements).
- Stable health status as defined by absence of a health event satisfying the definition
of a SAE, or a change in an ongoing drug therapy due to therapeutic failure or
symptoms of drug toxicity, within 1 month prior to enrolment.
- Parent(s)/LAR(s) available and accessible for active surveillance contacts.
- Parent(s)/LAR(s) and (if age-appropriate, subjects) who, in the investigator's
opinion, can and will comply with the requirements of the protocol as documented by
signature on the informed consent document.
- Female subjects of non-childbearing potential (pre-menarche) may be enrolled in the
study.
Query!
Minimum age
6
Months
Query!
Query!
Maximum age
9
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Previous vaccination with an A/California/7/2009 (H1N1)v-like virus vaccine.
- Medical history of physician-confirmed infection with an A/California/7/2009
(H1N1)v-like virus.
- Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
which, even if stable, are deemed by the investigator to render the potential subject
or parent(s)/LAR(s) unable/unlikely to provide accurate safety reports.
- Presence of a temperature = 38.0ºC (= 100.4ºF) by any route or method, or acute
symptoms greater than "mild" severity on the scheduled date of first vaccination.
NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved,
vaccination occurs within the window specified by the protocol, and all other
eligibility criteria continue to be satisfied.
- Diagnosed with cancer, or treatment for cancer, within 3 years.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination (no laboratory testing required).
- Receipt of systemic glucocorticoids within 1 month prior to study enrollment (first
dose of study vaccine), or any other cytotoxic or immunosuppressive drug within 6
months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are
allowed.
- Receipt of any immunoglobulins and/or any blood products within 6 months of study
enrollment or planned administration of any of these products during the study period.
- Any significant disorder of coagulation or treatment with warfarin derivatives or
heparin. Persons receiving individual doses of low molecular weight heparin are
eligible if no such doses are given in the 24 hours before a study vaccination.
Persons receiving prophylactic antiplatelet medications, e.g., low-dose
acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are
eligible.
- An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6
weeks of receipt of seasonal influenza vaccine.
- Administration of any licensed live attenuated vaccine within 4 weeks before the first
vaccination or of any licensed inactivated vaccine within 2 weeks before the first
vaccination.
- Planned administration of any vaccine not foreseen by the study protocol between Day 0
and Day 42. Routine childhood vaccinations are exempted if they cannot be delayed, but
they must not be administered on the same day as the H1N1 vaccine candidate.
- Planned use of a pandemic monovalent A/California/7/2009 (H1N1)v-like virus vaccine
other than the study vaccines during the study period.
- Planned administration of seasonal trivalent influenza vaccine during the 4 month
period following Day 0.
- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccine(s) within 30 days before the first dose of study vaccine, or planned use
during the study period.
- Any known or suspected allergy to any constituent of influenza vaccines (including egg
proteins or mercurial preservatives); a history of anaphylactic-type reaction to
consumption of eggs; or a history of severe adverse reaction to a previous influenza
vaccine.
- Child in care.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/02/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/09/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
6154
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Kippa Ring
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Carlton
Query!
Recruitment postcode(s) [1]
0
0
4021 - Kippa Ring
Query!
Recruitment postcode(s) [2]
0
0
3053 - Carlton
Query!
Recruitment outside Australia
Country [1]
0
0
Brazil
Query!
State/province [1]
0
0
Santa Catarina
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
São Paulo
Query!
Country [3]
0
0
Colombia
Query!
State/province [3]
0
0
Cali
Query!
Country [4]
0
0
Costa Rica
Query!
State/province [4]
0
0
San Jose
Query!
Country [5]
0
0
Mexico
Query!
State/province [5]
0
0
Morelos
Query!
Country [6]
0
0
Mexico
Query!
State/province [6]
0
0
Durango
Query!
Country [7]
0
0
Mexico
Query!
State/province [7]
0
0
Mexico city
Query!
Country [8]
0
0
Mexico
Query!
State/province [8]
0
0
Monterrey
Query!
Country [9]
0
0
Philippines
Query!
State/province [9]
0
0
Dasmariñas, Cavite
Query!
Country [10]
0
0
Philippines
Query!
State/province [10]
0
0
Muntinlupa
Query!
Country [11]
0
0
Philippines
Query!
State/province [11]
0
0
Sampaloc, Manila
Query!
Country [12]
0
0
Singapore
Query!
State/province [12]
0
0
Singapore
Query!
Country [13]
0
0
Thailand
Query!
State/province [13]
0
0
Bangkok
Query!
Country [14]
0
0
Thailand
Query!
State/province [14]
0
0
Khon Kaen
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1
flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years
of age.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01051661
Query!
Trial related presentations / publications
Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01051661
Download to PDF